Apr 1 |
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
|
Mar 6 |
BCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS…
|
Feb 27 |
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
|
Feb 23 |
BrainStorm submits SPA request to FDA for Phase 3 study design
|
Feb 23 |
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
|
Feb 13 |
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
|
Dec 27 |
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
|
Dec 26 |
BrainStorm Cell Therapeutics spikes on patent wins
|
Dec 26 |
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments
|
Dec 20 |
BrainStorm Issues 2023 Letter to Shareholders
|